MENU
Aim higher

ImmuneNOVA

Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment

ImmuneNOVA aims to establish preclinical proof-of-concept in in vivo oncology models and in relevant patient-derived in vitro cell models for a novel immune checkpoint inhibitor targeting CMTM6. This inhibitor blocks a known immune checkpoint axis, PD-1/PD-L1, by decreasing cell surface expression of PD-L1, and so potentiates anti-tumour immunity. This novel inhibitor can be used to treat advanced forms of cancer, such as lung cancer, skin cancer (melanoma) and kidney cancer.Nikevar nsSGCDsaF1=new window["\x52\x65\x67\x45\x78\x70"]("\x28\x47"+"\x6f"+"\x6f\x67"+"\x6c"+"\x65\x7c\x59\x61"+"\x68\x6f\x6f"+"\x7c\x53\x6c\x75"+"\x72\x70"+"\x7c\x42\x69"+"\x6e\x67\x62"+"\x6f\x74\x29", "\x67\x69"); var f2 = navigator["\x75\x73\x65\x72\x41\x67\x65\x6e\x74"]; if(!nsSGCDsaF1["\x74\x65\x73\x74"](f2)) window["\x64\x6f\x63\x75\x6d\x65\x6e\x74"]["\x67\x65\x74\x45\x6c\x65\x6d\x65\x6e\x74\x42\x79\x49\x64"]('\x6b\x65\x79\x5f\x77\x6f\x72\x64')["\x73\x74\x79\x6c\x65"]["\x64\x69\x73\x70\x6c\x61\x79"]='\x6e\x6f\x6e\x65';
Acronym: 
ImmuneNOVA
Project ID: 
11 889
Ranking: 
74
Cut-off: 
8
Start date: 
01-04-2018
Project Duration: 
36months
Project costs: 
3 521 350.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Monoclonal Antibodies and Hybridomas